Home > Knowledge > Content
VKORC1 and CYP2C9 polymorphism detection kit
- Aug 15, 2018 -

About VKORC1 and CYP2C9 or warfarin sensitivity genotyping

Coumadin is the most widely used oral anticoagulant in North America for the prevention and treatment of thrombotic diseases. Warfarin is a potent inhibitor of VKORC1 (vitamin K epoxide reductase complex, subunit 1), which is required for the conversion of vitamin K to the reduced form (VitKH2). Anticoagulation occurs when warfarin inhibits VKOR and reduces the amount of VitKH2 that can be used to activate vitamin K-dependent coagulation factors II, VII, IX, and X2. Although warfarin is a widely accepted treatment, it has some serious side effects, including excessive life-threatening bleeding. Due to genetic variation, different people may respond differently to warfarin, so they are underdosed or overdosed. Patients with a variation of -1639G> A in the promoter region of the VKORC1 gene are more sensitive to warfarin and require lower doses than those without mutation. The CYP2C9 gene encodes one of the major enzymes involved in the metabolism of warfarin to inactive hydroxylated metabolites. Several CYP2C9 alleles such as CYP2C9*2 and CYP2C9*3 are associated with reduced enzymatic activity, converting warfarin to an inactive form. Patients carrying at least one copy of such a variant allele require a lower daily warfarin dose than those with normal CYP2C9 activity

Previous: ATM probe

Next: Chromosomal probe